Isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: Updated safety run-in results from the randomized phase 3 ithaca study için istatistikler
Toplam ziyaret
| views | |
|---|---|
| Isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: Updated safety run-in results from the randomized phase 3 ithaca study | 0 |
Aylık toplam ziyaret
| views | |
|---|---|
| Aralık 2025 | 0 |
| Ocak 2026 | 0 |
| Şubat 2026 | 0 |
| Mart 2026 | 0 |
| Nisan 2026 | 0 |
| Mayıs 2026 | 0 |
| Haziran 2026 | 0 |
Dosya Ziyaretleri
| views | |
|---|---|
| Sevindik-Gokmen-2022.pdf | 8 |
